Literature DB >> 22423008

A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma.

Jianguang Ji1, Kristina Sundquist, Jan Sundquist.   

Abstract

Hepatitis D virus (HDV) is dependent on the presence of hepatitis B virus (HBV) for transmission and replication because of its inability to produce its own coat. It remains unclear whether HDV infection increases the risk of hepatocellular carcinoma. Using the Swedish Hospital Discharge Register and Outpatient Registry, we identified 9160 patients with chronic HBV infection between 1997 and 2008, of whom 327 had chronic HDV infection and 323 had acute HDV infection. Standardized incidence ratios (SIRs) were calculated for these patients compared with the general population. The risk of hepatocellular carcinoma was greatly increased in patients with HBV and HDV (SIR = 137.17, 95% confidence interval [CI] = 62.19 to 261.51). The risk of hepatocellular carcinoma among patients with HBV and HDV was increased (SIR = 6.11, 95% CI = 2.77 to 11.65) when patients with chronic HBV infection alone were used as the reference population. Similar results were observed for patients with chronic HDV infection (SIR = 99.26, 95% CI = 42.39 to 196.55). Our findings indicate that HDV is a strong risk factor for hepatocellular carcinoma.

Entities:  

Mesh:

Year:  2012        PMID: 22423008     DOI: 10.1093/jnci/djs168

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  36 in total

Review 1.  HBV/HDV Coinfection: A Challenge for Therapeutics.

Authors:  Christopher Koh; Ben L Da; Jeffrey S Glenn
Journal:  Clin Liver Dis       Date:  2019-05-24       Impact factor: 6.126

Review 2.  Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection.

Authors:  Nicole D Ferrante; Vincent Lo Re
Journal:  Curr HIV/AIDS Rep       Date:  2020-08       Impact factor: 5.071

3.  Prevalence of Hepatitis B and Hepatitis D Virus Infections in the United States, 2011-2016.

Authors:  Eshan U Patel; Chloe L Thio; Denali Boon; David L Thomas; Aaron A R Tobian
Journal:  Clin Infect Dis       Date:  2019-08-01       Impact factor: 9.079

4.  Artificial neural network model for predicting 5-year mortality after surgery for hepatocellular carcinoma: a nationwide study.

Authors:  Hon-Yi Shi; King-Teh Lee; Jhi-Joung Wang; Ding-Ping Sun; Hao-Hsien Lee; Chong-Chi Chiu
Journal:  J Gastrointest Surg       Date:  2012-08-10       Impact factor: 3.452

Review 5.  Molecular mechanisms of the preventable causes of cancer in the United States.

Authors:  Erica A Golemis; Paul Scheet; Tim N Beck; Eward M Scolnick; David J Hunter; Ernest Hawk; Nancy Hopkins
Journal:  Genes Dev       Date:  2018-06-26       Impact factor: 11.361

6.  Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.

Authors:  Christopher Koh; Laetitia Canini; Harel Dahari; Xiongce Zhao; Susan L Uprichard; Vanessa Haynes-Williams; Mark A Winters; Gitanjali Subramanya; Stewart L Cooper; Peter Pinto; Erin F Wolff; Rachel Bishop; Ma Ai Thanda Han; Scott J Cotler; David E Kleiner; Onur Keskin; Ramazan Idilman; Cihan Yurdaydin; Jeffrey S Glenn; Theo Heller
Journal:  Lancet Infect Dis       Date:  2015-07-16       Impact factor: 25.071

7.  Hepatitis D Viremia Among Injection Drug Users in San Francisco.

Authors:  Parag Mahale; Peter V Aka; Xiaohua Chen; Ping Liu; Benjamin J Fram; Alan S Wang; Scott Simenel; Fan-Chen Tseng; Sabrina Chen; Brian R Edlin; Jeffrey S Glenn; Thomas R O'Brien
Journal:  J Infect Dis       Date:  2018-05-25       Impact factor: 5.226

8.  Long-term therapy of chronic delta hepatitis with peginterferon alfa.

Authors:  T Heller; Y Rotman; C Koh; S Clark; V Haynes-Williams; R Chang; R McBurney; P Schmid; J Albrecht; D E Kleiner; M G Ghany; T J Liang; J H Hoofnagle
Journal:  Aliment Pharmacol Ther       Date:  2014-05-11       Impact factor: 8.171

Review 9.  Hepatitis D and hepatocellular carcinoma.

Authors:  Zaigham Abbas; Minaam Abbas; Sarim Abbas; Lubna Shazi
Journal:  World J Hepatol       Date:  2015-04-18

10.  Treatment options for hepatitis delta virus infection.

Authors:  Benjamin Heidrich; Michael P Manns; Heiner Wedemeyer
Journal:  Curr Infect Dis Rep       Date:  2013-02       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.